Inhaled corticosteroids in obstructive airway disease

Respiratory Care

Volumn 52, Issue 7, 2007, Pages 852-858

  Phua, Ghee Chee ^a,b   MacIntyre, Neil R ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Administration; Aerosols; Asthma; Chronic obstructive pulmonary disease; Corticosteroids; Inhalation; Metered dose inhaler

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING DRUG; MOMETASONE FUROATE; NITRIC OXIDE; PLACEBO; SALMETEROL; TRIAMCINOLONE ACETONIDE;

ASTHMA; BONE DENSITY; CANDIDIASIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRY POWDER; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; GLAUCOMA; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; LOW DRUG DOSE; LUNG FUNCTION; METERED DOSE INHALER; MONOTHERAPY; MORTALITY; MYOPATHY; NEBULIZER; PEPTIC ULCER; PNEUMONIA; POWDER INHALER; PSYCHOSIS; SIDE EFFECT; SKIN BRUISING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; INHALATIONAL DRUG ADMINISTRATION; REVIEW; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 34548582005     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Bordley JE, Carey RA, Harvey AM. Preliminary observations on the effect of adrenocorticotrophic hormone in allergic diseases. Bull Johns Hopkins Hosp 1949;85(5):396-398.
2. Schwartz E. Oral cortisone therapy in intractable bronchial asthma. J Am Med Assoc 1951;147(18):1734-1737.
3. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972;1(5800):585-590.
4. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122(1):47-55.
5. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344(5):350-362.
6. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(3):418-424.
7. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148(3):245-254.
8. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102(4 Pt 1):531-538.
9. 2- agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1(3):200-206.
10. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(7):760-765.
11. Man SF, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2(1):78-82.
12. Adcock IM, Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc 2005;2(4)313-319; discussion 340-341.
13. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffrey PK, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155(5):1529-1534.
14. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggierie MP, Rogeri A, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150(6 Pt 1):1646-1652.
15. Fardon TC, Lee DKC, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170(9):960-966.
16. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12(6):1346-1353.
17. American Respiratory Care Foundation. Consensus Statement: Aerosols and delivery devices. Respir Care 2000;45(6):589-596. Erratum in Respir Care 2000(11):1416.
18. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001;323(7318):896-900.
19. Cates CJ, Bestall J, Adams N. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst Rev 2006 Jan 25;(1)CD001491.
20. Sin DD, Man J, Sharpe H, Gan WO, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292(3):367-376.
21. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277(11):887-891.
22. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000:343(5):332-336.
23. Becker A, Lemiere C, Berube D, Boulet LP, Ducharme FM, FitzGerald M, Kovesti T; Asthma Guidelines Working Group of the Canadian Network for Asthma Care. Summary of recommendations from the Canadian Asthma Consensus guidelines. CMAJ 2005;173(6 Suppl):S3-S11.
24. The global initiative for asthma (GINA). [Internet]. Available at www.ginasthma.com. (Accessed May 10, 2007)
25. Asthma in adults and schoolchildren. The General Practioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society and the Royal College of Paediatrics and Child Health. Thorax 1997;52 Suppl 1:S2-S8, S11-S15, S20-S21.
26. National Asthma Education and Prevention Program (NAEPP). [Internet]. Available at www.nhlbi.nih.gov/about/naepp/index.htm. (Accessed May 10, 2007)
27. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2003;(3):CD002308.
28. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 2006;130(5):1301-1311.
29. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al; START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomized double-blind trial. Lancet 2003;361(9363):1071-1076.
30. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164(8 Pt 1):1392-1397.
31. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352(15):1519-1528.
32. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002;57(4):309-316.
33. O'Byrne PM, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006;129(6):1478-1485.
34. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose of inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60(9):730-734.
35. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320(7246):1368-1373.
36. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbation and asthma-related deaths. Ann Intern Med 2006;144(12):904-912.
37. FDA Public Health Advisory: Serevent Diskus, Advair Diskus, Foradil Aerolizer. [Internet]. Available at www.fda.gov/cder/drug/advisory/LABA.htm. Updated 5/2006. (Accessed May 10, 2007)
38. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
39. Ernst P, McIvor A, Ducharme FM, Boulet LP, FitzGerald M, Chapman KR, et al; Canadian Asthma Guideline Group. Safety and effectiveness of long-acting inhaled β-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145(9):692-694.
40. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbation of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340(25):1941-1947.
41. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340(25):1948-1953.
42. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long term effects of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999;353(9167):1819-1823.
43. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320(7245):1297-1303.
44. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343(26):1902-1909.
45. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58(11):937-941.
46. 1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003;138(12):969-973. Erratum in: Ann Intern Med 2003;139(10):873.
47. Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003;22(1):1-2.
48. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343(26):1902-1909.
49. Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005;172(4):460-464.
50. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60(12):992-997.
51. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-789.
52. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; (1):CD003537.
53. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345(13):941-947.
54. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337(1):8-14.
55. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277(9):722-727.
56. Reynolds NA, Scott LJ. Ciclesonide. Drugs 2004;64(5):511-519; discussion 520-521.
57. Colice GL. New developments in inhaled corticosteroids. Allergy Asthma Proc 2006;27(5):332-340.
58. Colice GL. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin Pharmacother 2006;7(15):2107-2117.
59. Meltzer EO, Derendorf H. The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. Ann Allergy Asthma Immunol 2006;97(2)149-157.
60. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352(21):2163-2173.